BTCC
/
BTCC Square
/
Global Cryptocurrency
/
Spruce Biosciences Stock Surges 2,900% on FDA Breakthrough Therapy Designation
Spruce Biosciences Stock Surges 2,900% on FDA Breakthrough Therapy Designation
12
1
BTCCSquare news:
Spruce Biosciences (SPRB) has become the talk of the biotech world, with its stock skyrocketing nearly 2,900% in a week. The frenzy began after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its lead drug candidate, tralesinidase alfa enzyme replacement therapy (TA-ERT), for treating Sanfilippo Syndrome Type B.
The designation accelerates regulatory review and signals potential for a transformative therapy in a space where no effective treatment exists. Trading volatility has been extreme, with multiple halts as investors scramble to position themselves. The rally underscores how microcap biotech stocks can pivot on a single regulatory decision.
By:
